380 CARDIAC AND VASCULAR IMPAIRMENT IN PATIENTS WITH MILD PSORIASIS: A LONGITUDINAL STUDY. (15th December 2022)

• Record Type: Journal Article
• Authors: Cocuzza, Federica; Carciotto, Gabriele; Pistelli, Lorenzo; Parisi, Francesca; De Murtas, Elisabetta; Poleggi, Cristina; Campanella, Francesca; De Sarro, Rosalba; Vinciguerra, Paolo; Imbalzano, Egidio; Di Bella, Gianluca; Micari, Antonio; Dattilo, Giuseppe; Casale, Matteo
• Is Part Of: European heart journal supplements. Volume 24(2022)Supplement K
• Publication Date: 2022-12-15
• Subjects: Cardiology -- Periodicals; Cardiology -- Europe -- Periodicals; 616.12005
• DOI: 10.1093/eurheartjsupp/suac121.708
• Languages: English
• ISSNs: 1520-765X

Abstract

Abstract: Backgrounds: Psoriasis is a chronic skin inflammatory disease, characterized by immune-mediated reaction and hyperproliferation of keratinocytes. It is typically associated with several comorbidities; in particular, there are numerous evidence of a link between this condition and cardiovascular (CV) disease. Nevertheless, little is known about its role as an independent cardiovascular risk factor. Purpose: The aim of this longitudinal study is to evaluate the role of Psoriasis as an independent CV risk factor, to establish the relationship between severity and duration of Psoriasis and CV damage and to find reliable markers to stratify CV risk in these patients. Methods: 33 patients affected by mild Psoriasis without comorbidities were enrolled in this longitudinal study and were compared with 33 healthy subjects. The severity of Psoriasis was assessed with the PASI (Psoriasis Area and Severity Index) score: a score <10 was used to classify psoriasis as mild. Both groups underwent an echocardiogram, with evaluation of 2-dimensional strain (2D-SE), and a Doppler of carotid-femoral pulse wave velocity (PWV). The same evaluation was performed at 2-year follow-up. Results: A total of 66 patients was included: 33 (50%) with mild psoriasis without comorbidities and 33 (50%) healthy subjects. Comparable clinical and echocardiographic baseline characteristics were observed between the two groups, except for Global Longitudinal Strain (GLS), which was significantly lower (p=0.002) in the Psoriasis group (22.39 ± 2.28%) than in controls (24.15 ± 2.17%), and PWV, that was significantly lower (p=0.004) in controls (8.06±1.68 m/sec) than in the psoriasis group (9.23 ± 1.53 m/sec). Significant correlations between GLS, disease duration and patient age at diagnosis were found, as in coronary artery disease (CAD) and cardiomyopathies. At 2-year follow-up, no significant changes in demographic or clinical characteristics were found within the Psoriasis group. The PASI score did not change significantly, no patient needed any systemic therapy (6 needed an increase in topical drugs) and none of the patients developed any conventional cardiovascular risk factor. There were no significant differences in echocardiographic parameters and no CV events occurred. Conclusions: According to our data, mild Psoriasis determines subclinical cardiac and vascular damage. However, at two-year follow-up, no CV changes in initially healthy patients were found.